PA
SUPN icon

Profund Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Profund Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$403K Buy
8,673
+1,700
+24% +$81.6K 0.01% 643
2026
Q1 		$360K Sell
6,973
-2,316
-25% -$118K 0.01% 662
2025
Q4 		$462K Buy
9,289
+422
+5% +$20.5K 0.01% 594
2025
Q3 		$424K Buy
8,867
+187
+2% +$7.53K 0.01% 580
2025
Q2 		$274K Sell
8,680
-110
-1% -$3.52K 0.01% 739
2025
Q1 		$288K Buy
8,790
+1,151
+15% +$40.8K 0.01% 708
2024
Q4 		$276K Sell
7,639
-2,947
-28% -$104K 0.01% 812
2024
Q3 		$330K Sell
10,586
-608
-5% -$19K 0.01% 745
2024
Q2 		$299K Buy
11,194
+4,543
+68% +$132K 0.01% 723
2024
Q1 		$227K Sell
6,651
-3,118
-32% -$92.8K 0.01% 1012
2023
Q4 		$283K Buy
9,769
+109
+1% +$2.89K 0.01% 814
2023
Q3 		$266K Buy
9,660
+1,454
+18% +$44.3K 0.01% 726
2023
Q2 		$247K Sell
8,206
-382
-4% -$13.4K 0.01% 839
2023
Q1 		$311K Buy
+8,588
New +$330K 0.02% 698
2019
Q1 		– Sell
-7,373
Closed -$245K – 1240
2018
Q4 		$245K Sell
7,373
-2,523
-25% -$108K 0.02% 907
2018
Q3 		$498K Sell
9,896
-1,414
-13% -$69.8K 0.02% 819
2018
Q2 		$677K Buy
11,310
+1,162
+11% +$60.2K 0.03% 571
2018
Q1 		$465K Buy
10,148
+2,719
+37% +$113K 0.02% 848
2017
Q4 		$296K Buy
7,429
+1,107
+18% +$43.7K 0.01% 1136
2017
Q3 		$253K Sell
6,322
-2,921
-32% -$126K 0.01% 1215
2017
Q2 		$398K Buy
9,243
+526
+6% +$18.7K 0.02% 900
2017
Q1 		$273K Sell
8,717
-986
-10% -$26.4K 0.01% 1215
2016
Q4 		$245K Buy
+9,703
New +$217K 0.01% 1343

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Profund Advisors's SUPN Position: Q2 2026 in Review

Profund Advisors increased its Supernus Pharmaceuticals (SUPN) stake by 24% in Q2 2026, buying an estimated $81.6K and bringing the position to 8,673 shares worth $403K. The position accounts for 0.01% of the portfolio, ranked #643.

Profund Advisors first reported a position in SUPN in Q4 2016 and has held it in 23 quarters since. The position peaked at $677K in Q2 2018. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Profund Advisors held 8,673 shares of Supernus Pharmaceuticals worth $403K as of Q2 2026.
  • Profund Advisors bought 1,700 Supernus Pharmaceuticals shares in Q2 2026, an estimated $81.6K.
  • Supernus Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q2 2026, its #643 holding.
  • Profund Advisors first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 23 quarters since.
  • Profund Advisors's Supernus Pharmaceuticals position peaked at $677K in Q2 2018.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.